After four decades of investigating mechanisms involved in ischemic brain injury, we have yet to develop an FDA-approved neuroprotective agent. Is reversing translational research the answer?

You can explore this new paradigm in Pre-Conference Symposium II at the AHA/ASA’s International Stroke Conference 2018.

“Stroke in the Lab World: Reversing Stroke Translational Research — Bedside-to-Bench and Back Again” will be held on Jan. 23 in Theater 411 at the Los Angeles Convention Center. It will feature leading researchers who have successfully achieved reverse translation, starting with human samples and applying cutting-edge big data techniques to identify genes/proteins of relevance.

Attendees will further explore examples of next steps needed to understand molecular mechanisms implicated by the genes/proteins identified by these new -omic techniques.

There is a separate fee to attend. Register here.

Symposium Schedule
1 p.m.
“Failure of Traditional Forward Translation: The Case of Neuroprotection”
Jin-Moo Lee, MD, PhD, St. Louis, Missouri

1:15 p.m.
“Genomics Approach to Reverse Translation”
Daniel Woo, MD, Cincinnati, Ohio

1:55 p.m.
“Probing Biofluids to Understand Disease Pathogenesis: A Transcriptomics Approach”
Frank Ray Sharp, MD, Sacramento, California

2:35-2:45 p.m.
Break

2:45 p.m.
“Integrating Big Data Across the Omics: A Systems Biology Approach”
Philip De Jager, MD, New York

3:25 p.m.
“Bedside-to-Bench-to-Drug Target”
Martin Dichgans, MD, Munich, Germany

4:05 p.m.
“Harvesting Human Cells to Develop ‘Disease-in-a-Dish’”
Adam Engler, PhD, La Jolla, California

4:45 p.m.
Q&A